The transplantation of a bioartificial pancreas has been regarded as a potential method for successful islet transplantation without any immunosuppressive agents. The subcutaneous site is a very attractive site for transplantation of a bioartificial pancreas because of its advantage of an easy operation site. Our group has been reporting that transplantation of a bioartificial pancreas to the subcutaneous site can reverse hyperglycemia in diabetic recipients. Regarding shapes of a bioartificial pancreas, it is believed that a bag form has an advantage because it is easy to prepare a large quantity. Our group previously reported successful transplantation of a bioartificial pancreas in bag form, a mesh-reinforced polyvinyl alcohol bag (MRPB), implanted in the peritoneal cavity. We also reported that the effect of subcutaneous islet transplantation can be greatly improved with prevascularization treatment. In the present study, we attempted to combine MRPB to our protocol of subcutaneous prevascularization. The main problem of this trial is that the procedure of MRPB implantation injures the prevascularized blood vessel networks. To solve this problem, we made a slight alternation in our protocol, and designed new devices on the basis of MRPB. The new devices, possessing the ability to induce neovascularization, were prepared by collagen coating on the surface of MRPB and were implanted with/without different doses of FGF-2 impregnated in gelatin microspheres. When using 5 µg of FGF-2, more blood vessels were observed on the surface of type I/IV collagen-coated MRPB compared with the original MRPB and type I collagen-coated MRPB. Quite a few blood vessels were observed either around the injection site of 50 µg of FGF-2 impregnated in gelatin microspheres alone or around the implantation site of FGF-2-free gelatin microspheres and type I collagen-coated MRPB or type I/IV collagen-coated MRPB. Here we demonstrated that the combination of both FGF-2 impregnated in gelatin microspheres and collagen-coated MRPB could give an effective system of neovascularization suitable for subcutaneous implantation of a bioartificial pancreas.
INTRODUCTION
ity to protect islets from immunorejection, has been regarded as a potential method for successful islet transplantation without any immunosuppressive agents. Several Transplantation of pancreas or islets is potentially a very useful therapy for diabetes mellitus. Although islet different approaches have been reported to realize an ideal bioartificial pancreas (2, 6) . We have investigated transplantation is more attractive than pancreas organ transplantation because of its easier operation, the results several kinds of bioartificial pancreas, such as islets encapsulated in agarose hydrogel microbeads (7) , islets en-of islet transplantation have been disappointing compared to those of pancreas transplantation until recently. Sha-capsulated in agarose/poly(styrene sulfonic acid) mixed gel microbeads (8) , MIN6 insulinoma cells enclosed piro et al. reported a new protocol that has led to much higher success rates, with almost all patients achieving with polyvinyl alcohol hydrogel membrane (5) , and others (4, 20) , and reported the recovery from hyperglyce-insulin independence (9) . However, this successful new protocol, the Edmonton protocol, needs chronic use of mia in diabetic recipients. The transplantation site of a bioartificial pancreas immunosuppressive agents.
A bioartificial pancreas, composed of encapsulated was one of the important issues for successful transplantation. The subcutaneous site is a very attractive site for islets in a semipermeable membrane possessing the abil-528 SAKURAI ET AL. transplantation because of its advantage of ease of oper-accomplished through a swelling process of the freezedried gelatin microspheres by an aqueous solution of ation. We have reported that transplantation of a bioartificial pancreas to the subcutaneous site could reverse FGF-2. Briefly, 30 µl of human recombinant FGF-2 solution (kindly supplied by Kaken Pharmaceutical Co., hyperglycemia in diabetic recipients (3, 11, 12, 20) . In these reports, we suggested that induction of neovasculariza-Tokyo, Japan), with an isoelectric point of 9.6, was dropped onto 2 mg of sterilized gelatin microspheres; tion at the subcutaneous site before transplantation of islet/bioartificial pancreas is a deciding factor in the suc-the resulting microspheres were maintained at 4°C for 6 h to obtain gelatin microspheres incorporating FGF-2. cessful islet/bioartificial pancreas transplantation.
Regarding the shape of a bioartificial pancreas to cure Preparation of MRPB diabetes mellitus, it is thought that a bioartificial pan-MRPB was prepared by a method previously described creas in bag form has high potential to be used clinically (4) . Briefly, the framework of the bioartificial pancreas because of its ease of preparation in large quantity. We in bag form (1.5 × 1.0 × 0.1 cm) was made by polyethylpreviously reported successful transplantation of a bioene terephthalate (PET) mesh sheet with a silicone rubartificial pancreas in bag form, a mesh-reinforced polyber sheet used as a spacer. The resulting PET-mesh bag vinyl alcohol bag (MRPB), implanted in the peritoneal with silicone rubber spacer was sterilized, and washed cavity (4) . The use of MRPB in our subcutaneous islet/ with sterile 6 N HClaq and sterile distilled water, then bioartificial pancreas transplantation system has the poimmersed in sterile 3% aqueous solution of polyvinyl tential to cause damage to the preinduced vascular netalcohol (PVA). The polymer had a number-average moworks when MRPB is implanted to a prevascularized sublecular weight of 3.87 × 10 5 and a degree of saponificacutaneous site. To overcome this problem, we attempted tion of 99.8 mol%. After excess PVA solution was reto add the ability to induce neovascularization to MRPB. moved, PVA solution was cross-linked by one cycle of In this study, we evaluated the ability of the newly frozen-thaw method, then the spacer was removed and designed devices to induce neovascularization in normal the mouth of this device was closed by heat sealer to rats. obtain MRPB. MRPB was stored at 4°C in phosphate-MATERIALS AND METHODS buffered saline (PBS) until use.
Preparation of Gelatin Microspheres Preparation of Modified MRPBs Incorporating FGF-2
MRPB was dipped in sterile 5% (w/v) aqueous solu-Gelatin microspheres were prepared through glutaraltion of sodium tetraborate for 10 s at room temperature, dehyde (GA) cross-linking method (17). Briefly, 5 ml of and immersed in an aqueous solution of collagen type I 10 wt% aqueous solution of acidic gelatin (Nitta Gelatin (Cellmatrix type I-C, Nitta Gelatin Co.) or of collagen Co., Osaka, Japan), with a molecular weight of 99,000 type I/type IV (Cellmatrix type IV, Nitta Gelatin Co.) and an isoelectric point of 5.0, was added to 175 ml of mixture (6:4, v/v) for 10 min on ice. After collagen was olive oil while stirring at 420 rpm at 37°C for 10 min to cross-linked by incubation at 37°C for 15 min, excess yield a water-in-oil emulsion. The emulsion was cooled collagen was removed by washing with sterile distilled in an ice-water bath, followed by further continuous stirwater. ring for 30 min to induce spontaneous gelation of the gelatin aqueous solution. After addition of 50 ml of ace-Implantation of a New Immunoisolation Device tone, the emulsion was further stirred at 420 rpm for 1
Possessing the Ability to Induce Neovascularization h. The resulting microspheres were washed with acetone Male Lewis rats, 8-10 weeks of age, were anestheand isopropyl alcohol three times, respectively, centritized with diethyl ether. Bilateral paramedian longitudial fuged at 2500 × g for 5 min, and dried. To 200 mg of incisions were made at the back of the rat and two subthe resulting dried gelatin microspheres, 200 ml of 0.1% cutaneous pockets were made laterally to the incisions Tween 80 aqueous solution containing 1 ml of 25% GA in each side by gentle blunt dissection. One MRPB/modaqueous solution was added and stirred at 4°C for 24 h ified MRPB or none was inserted into each pocket, after to facilitate their cross-linking. After collecting by cenwhich the different quantities of FGF-2 impregnated in trifugation at 2500 × g for 5 min at 4°C, the microgelatin microspheres were injected to the muscular side spheres were further agitated in 100 ml of 10 mM glyof the MRPB/modified MRPB using a pipette, and incicine aqueous solution at 37°C for 1 h to block residual sions were closed using surgical sutures. aldehyde group of unreacted GA. The resulting micro-Scanning Electron Microscopy (SEM) Analysis spheres were finally washed with distilled water three of MRPB and Modified MRPBs times, centrifuged at 2500 × g for 5 min, and freezedried with distilled water.
Modified MRPBs were fixed in 2.5% (v/v) GA in phosphate buffer solution and washed with PBS three FGF-2 impregnation into gelatin microspheres was times. A part of MRPB and modified MRPBs were cut I collagen-coated MRPB and type I/IV collagen-coated MRPB had a lot of large pores and typical three-dimen-out and dehydrated in a graded series of water/ethanol solutions and freeze-dried with t-butyl alcohol. Samples sion structures of collagen gel on their surface, though the original MRPB had a smooth surface. From these were Pt-sputtered and analyzed by SEM equipment (Hitachi S-2380N).
figures, the diameter of the pores was estimated approximately as 50-100 µm in type I collagen-coated MRPB Histological Analysis and 10-50 µm in type I/IV collagen-coated MRPB. For assessment of the neovascularization effect of the new immunoisolation device possessing the ability to in-Assessment of Neovascularization Effect of MRPB duce neovascularization, 2 weeks after implantation, the and Modified MRPBs With FGF-2 Impregnated subcutaneous tissues of the implantation site were rein Gelatin Microspheres moved from the sacrificed animals and fixed in 4% para-In the rats receiving 5 µg of FGF-2 impregnated in formaldehyde in phosphate buffer solution for 20 h. The gelatin microspheres, more blood vessels were observed samples were embedded in paraffin and sectioned on a on the surface of type I/IV collagen-coated MRPB than rotary microtome at a thickness of 4 µm. The sections that of MRPB and type I collagen-coated MRPB. There were stained with hematoxylin and eosin, and examined was no obvious difference in the number of blood vesby light microscopy. sels between muscular and cutaneous sides of MRPBs, though FGF-2 impregnated in gelatin microspheres was Immunohistochemical Staining injected to the muscular side of MRPB/modified MRPBs The sections of subcutaneous tissue samples were ( Fig. 2 ). prepared as described above and immunostained for ei-In the rats receiving 10 µg of FGF-2 impregnated in ther platelet endothelial cell adhesion molecules-1/CD31 gelatin microspheres, more blood vessels were observed (PECAM-1), Factor VIII related antigen [von Willein comparison to the rat receiving 5 µg of FGF-2 ( Fig. 3 ). brand factor (vWF)], Ulex europaeus-I lectin (UEA-I),
Quite a few blood vessels were observed either around or α-smooth muscle actin (α-SMA) by the streptavidinthe injection site of 50 µg of FGF-2 impregnated in gelabiotin complex (SAB) method. Briefly, after the sections tin microspheres alone ( Fig. 4A ) or around the implantawere deparaffinized and then hydrated, they were treated tion site of FGF-2-free gelatin microspheres and type I in 10 mM citrate buffer (pH 6.0) with a 100-V, 500-W collagen-coated MRPB or type I/IV collagen-coated MRPB microwave for 5 min three times to restore the immuno-( Fig. 4B, C) . reactivity of antigens except for α-SMA. Endogeneous
The detection of blood vessels was supported by imperoxidase activity was blocked by treatment with 3% munohistochemical staining for anti-PECAM-1, anti-vWF, hydrogen peroxide for 10 min, and nonspecific binding and anti-UEA-I, known as markers of endothelial cells was blocked by treatment either with 10% normal rabbit of blood vessels, and α-SMA, the marker of smooth serum for 30 min in PECAM-1, vWF, and α-SMA stainmuscle cells of blood vessels. The blood vessels with ing, or with 10% normal goat serum in UEA-I staining, several scales in diameter were positively stained by respectively. After sections were incubated with either anti-PECAM-1, anti-vWF, anti-UEA-I, and anti-α-SMA mouse anti-PECAM-1 (monoclonal, Secotec Ltd., 1 : 50), antibodies ( Fig. 5 ). mouse anti-vWF (monoclonal, NeoMarkers, 1 : 10), rabbit anti-UEA-I (polyclonal, Sigma, 1 : 50), or mouse anti-DISCUSSION α-SMA (monoclonal, DAKO, 1 : 400) antibody overnight,
The transplantation of a bioartificial pancreas has they were incubated either with biotinated rabbit antibeen regarded as a potential method for successful islet mouse IgG antibody (Nichirei, Tokyo, Japan) in PECAM-1, transplantation without any immunosuppressive agents. vWF, and α-SMA staining, or with biotinated goat anti-
The choice of site for bioartificial pancreas transplantarabbit IgG antibody (Nichirei) in UEA-I for 30 min, and tion is very important in acquiring successful islet transthen incubated with peroxidase-labeled avidin-biotin plantation. It is thought that the subcutaneous site is very (Nichirei) for 30 min. The sections were treated with 0.02% attractive in comparison to other transplantation sites beof 3,3′-diaminobenzidine (Dojindo, Kumamoto, Japan) cause of the ease of operation with minimally invasive solution for 10 min, and counterstained either with heprocedures. Recently, Weir et al. reported the subcutanematoxylin in PECAM-1, vWF, and UEA-I staining, or ous allotransplantation (mice to mice) (10) and xenowith methyl green in α-SMA staining, respectively. transplantation (rats to mice) (18). In their reports, it is RESULTS described that the induction of neovascularization before Surface Structures of MRPB and Modified MRPBs islet transplantation did not work to improve the results of islet transplantation, although the generation of neo-The surface structures of MRPB and modified MRPB were observed using SEM equipment (Fig. 1) . The type vascularization around the graft is absolutely necessary to reverse hyperglycemia in diabetic recipients. In the ies, bioartificial pancreas in bag form seems to have enormous potentialities to satisfy these requirements. last several years, we have reported that isotransplantation (11, 12) , allotransplantation (3), and xenotransplan-In our recent studies, we are trying to apply our previously studied MRPB to our protocol of subcutaneous tation (20) of encapsulated islets into a subcutaneous site can induce normoglycemia in diabetic recipients. In these prevascularization for bioartificial pancreas transplantation. The main problem of this trial is that MRPB injures studies, we first induced neovascularization at the subcutaneous site, and 2 weeks after that the bioartificial the prevascularized blood vessel networks when they are transplanted. To solve this problem, we changed the pro-pancreas was transplanted at the prevascularized site, suggesting that the induction of prevascularization is a tocol and made a modification on MRPB. That is, an immunoisolation device possessing the ability to induce very important factor for the good results of bioartificial pancreas transplantation.
neovascularization was implanted at the future transplantation site of islet cells. Then, 2 weeks after implan-Several shapes of a bioartificial pancreas have been investigated to realize an ideal bioartificial pancreas. Mi-tation, an injectable bioreactor, composed of islets and sol matrices, is injected into the previously implanted crobeads form, tube form, bag form, sheet form, and other forms have been tested and reported (2, 6) . It is immunoisolatory device. In this study, we evaluated the efficiency of modified MRPB and prevascularization thought that the ideal bioartificial pancreas for clinical use should be easy and reproducible to prepare on a method with FGF-2. In 1970s and 1980s, the membranes developed for larger scale and in larger quantities. Previously, we reported that transplantation of bioartificial pancreas in microfiltration and ultrafiltration were applied to the semipermeable membranes of immunoisolation to protect is-bag form, MRPB, in the peritoneal cavity could reverse hyperglycemia in diabetic recipients (4) . From our stud-lets from immunorejection in a bioartificial pancreas (15, 
19)
. In these early studies, it is thought that one of the In addition, recent advances in cell biology have elucidated that growth factors such as vascular endothelial reasons the cells lost their function was the overgrowth of fibroblasts around the implanted bioartificial pan-growth factor and FGF-2 greatly contributed to tissue regeneration at various stages of cell proliferation and dif-creas. We previously reported that MRPB can overcame this problem because few cells could adhere to the sur-ferentiation (14). These growth factors have been used to promote neovascularization. However, the half-life pe-face of immunoisolatory membranes of MRPB (4,5). Therefore, we need blood vessels to adhere, but, on the other riod of FGF-2 in the body is too short to exert its biological activity effectively when injected in the free form. hand, we need to prevent the fibroblast overgrowth on the surface of immunoisolatory membranes of MRPB.
It was reported that impregnation of FGF-2 in gelatin hydrogel strongly induced neovascularization around the It has been reported that cultured endothelial cells on or within extracellular matrix (ECM) substrates such as implantation site (16). Our group used the gelatin microspheres incorporating FGF-2 for inducing neovasculari-types I, III, IV, or V collagen, fibrin, fibronectin, laminin, and Matrigel form capillary-like structures (13). On zation in a subcutaneous site (3, 20) . On the basis of these findings, we designed the device system composed of the other hand, when implanted subcutaneously, fibrin or Matrigel results in blood vessel ingrowth, but type I the gelatin microspheres incorporating FGF-2 and type I collagen-coated or type I/IV collagen-coated MRPB to collagen does not (13). Results of research evaluating the influence of ECM substrates are often difficult to com-obtain the immunoisolation devices possessing the ability to induce neovascularization. pare because of different research methods. Consequently, the most effective ECM substrate has not been demon-It is known that types I and IV collagen have an isoelectric point between 8.0 and 8.9. The coating of type strated unequivocally. These observations motivated us to study the effect of both type I collagen and type I/IV I collagen or type I/IV collagen on the surface of MRPB was performed by making negatively charged MRPB collagen mixture on vascular formation in our system. and forming an ion complex between MRPB and type I in the number of blood vessels was observed between muscular and cutaneous sides of the devices may be that collagen or type I/IV collagen. The negatively charged MRPB was prepared by treatment with an aqueous solu-the pockets made for device implantation were generally bigger than the size of MRPBs, and FGF-2 released tion of sodium tetraborate (Fig. 6) .
The surface structure of the implanted device is one from gelatin microspheres could easily defuse to the cutaneous side. of the important factors that affect the degree of neovascularization induction (13). We observed the surface struc-
The dose dependency of FGF-2 impregnated in gelatin microspheres was obviously observed. When we used tures of MRPB and modified MRPBs by SEM equipment. Obviously, a lot of large pores were observed on 10 µg of FGF-2 impregnated in gelatin microspheres, more effective induction of neovascularization was ob-the surfaces of type I collagen-coated and type I/IV collagen-coated MRPBs. These large pores were derived served in comparison with the use of 5 µg of FGF-2, although the type I collagen-coated and type I/IV colla-from typical three-dimension structures of each collagen gel. Brauker et al. investigated the foreign-body responses gen-coated MRPBs were surrounded by a small amount of exudate. When we used more than 20 µg of FGF-2 elicited by over 150 membranes of various pore sizes (1) . In their report, they described that membranes with impregnated in gelatin microspheres, the type I collagen-coated and type I/IV collagen-coated MRPBs were large pore sizes (5-15 µm) resulted in vascularized capsules containing blood vessels in direct contact with the enclosed with a large quantity of exudate, including erythrocytes. These findings suggested that the quantity of membrane surface but membranes with smaller pore sizes (0.02-5 µm) resulted in avascular capsules. On the FGF-2 impregnated in gelatin microspheres should be appropriately decided according to the situation. basis of these findings, it is suggested that type I collagen-coated and type I/IV collagen-coated MRPBs hav-To estimate the deciding factors of this system, we evaluated the neovascularization abilities of 50 µg of ing large pores on their surface possess enormous potentialities to induce neovascularization in direct contact FGF-2 impregnated in gelatin microspheres alone and type I collagen-coated MRPB or type I/IV collagen-with their membrane surfaces.
To assess the neovascularization abilities of newly coated MRPB with FGF-2-free gelatin microspheres. The observation of quite a few neovascularizations in designed devices, we implanted them at the subcutaneous site of rats and examined the subcutaneous tissues these cases suggests that it is important to use both FGF-2 impregnated in gelatin microspheres and collagen-surrounding the devices by histological analysis. Greater neovascularization around subcutaneously implanted type coated MRPB.
As to the reason of the high efficiency of type I/IV I/IV collagen-coated MRPB with 5 µg of FGF-2 was observed in comparison with type I collagen-coated MRPB collagen-coated MRPB with FGF-2 impregnated in gelatin microspheres, it is likely that endothelial cells in-and original MRPB. These findings are consistent with previous reports suggesting that Matrigel, composed of duced to migrate for the type I/IV collagen-coated MRPB by FGF-2 could easily form tubular structures owing to type IV collagen and laminin, resulted in blood vessel ingrowth but type I collagen did not when implanted the structural and/or biochemical contribution of type I/IV collagen coating. Another possible reason is that FGF-2 subcutaneously (13). The reason no obvious difference released from gelatin microspheres might be trapped by type I/IV collagen coating on the surface of MRPB; as a result, the concentration of FGF-2 might be maintained higher and/or the half-life period of FGF-2 might be longer. Further study is now progressing. In summary, we have developed a new immunoisolatory device possessing the ability to induce neovascularization using both FGF-2 impregnated in gelatin microspheres and type I/IV collagen-coated MRPB.
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